×

Human Vascular Endothelial cell Growth Factor (VEGF) ELISA Kit

  • Cat.No.: AE11718HU

  • Reactivity: Human (Homo sapiens)

To Purchase AE11718HU

Size:
48T 96T
Price: Inquire

Reagent Preparation







Results demonstration







Assay Procedure Summary







Certificate



Product Details

Species Reactivity Human (Homo sapiens)
UniProt P15692
Abbreviation VEGFA
Alternative Names RP1-261G23.1; MGC70609; MVCD1; VEGF; VEGF-A; VPF; vascular endothelial growth factor isoform VEGF165|vascular permeability factor
Range 78.1-5000 pg/mL
Sensitivity 39 pg/mL
Sample Type Serum, Plasma, Other biological fluids
Detection Method Sandwich
Analysis Method Quantitive
Assay Duration 1-4.5h
Sample Volume 1-200 μL
Detection Wavelengt 450 nm

Test principle

This assay employs a two-site sandwich ELISA to quantitate VEGFA in samples. An antibody specific for VEGFA has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any VEGFA present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for VEGFA is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of VEGFA bound in the initial step. The color development is stopped and the intensity of the color is measured.
 

Product Overview


 

Components


Reagents

Quantity

Reagents

Quantity

Assay plate (96 Wells)

1

Instruction manual

1

Standard (lyophilized)

2

Sample Diluent

1 x 20 mL

Biotin-Conjugate (concentrate 100 x)

1 x 120 μL

Biotin-Conjugate Diluent

1 x 20 mL

Streptavidin-HRP  (concentrate 100 x)

1 x 120 μL

Streptavidin-HRP Diluent   

1 x 20 mL

Wash Buffer (concentrate 25 x)

1 x 20 mL

Substrate Solution

1 x 10 mL

Stop Solution

1 x 10 mL

Adhesive Films

4

 

Specificity

This assay has high sensitivity and excellent specificity for detection of Human VEGFA. No significant cross-reactivity or interference between Human VEGFA and analogues was observed.
 

Recovery

Matrices listed below were spiked with certain level of recombinant Human VEGFA and the recovery rates were calculated by comparing the measured value to the expected amount of Human VEGFA in samples.

Sample Type

Number

Recovery range (%)

Average(%)

Serum

10

90-101

96

EDTA plasma

10

89-97

93

Heparin plasma

10

91-99

95

 

Precision

Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision. Inter-assay Precision (Precision between assays) Three samples of known concentration were tested in forty separate assays to assess inter-assay precision. CV (%) = SD/meanX100 Intra-Assay: CV<8% Inter-Assay: CV<12%
 

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Human VEGFA and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample Type

1:2

1:4

1:8

1:16

Serum

78-89%

81-99%

92-103%

95-105%

EDTA plasma

91-101%

90-98%

93-101%

91-98%

Heparin plasma

92-103%

93-102%

92-99%

91-101%

 

Stability

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. The loss rate was determined by accelerated thermal degradation test. Keep the kit at 37°C for 4 and 7 days, and compare O.D.values of the kit kept at 37°C with that of at recommended temperature. (referring from China Biological Products Standard, which was calculated by the Arrhenius equation. For ELISA kit, 4 days storage at 37°C can be considered as 6 months at 2 - 8°C, which means 7 days at 37°C equaling 12 months at 2 - 8°C).
 

Sample collection and storage

Serum: Use a serum separator tube (SST) and allow samples to clot for two hours at room temperature or overnight at 2 - 8°C before centrifugation for 15 minutes at 1000 × g. Remove serum and assay immediately or aliquot and store samples at ≤ -20°C. Avoid repeated freeze-thaw cycles. Plasma: Collect plasma using EDTA, or heparin as an anticoagulant. Centrifuge for 15 minutes at 1000 × g at 2 - 8°C within 30 minutes of collection. Assay immediately or aliquot and store samples at ≤ -20°C. Avoid repeated freeze-thaw cycles. Other biological fluids: Centrifuge samples for 20 minutes at 1000 × g. Remove particulates and assay immediately or store samples in aliquot at -20°C or -80°C. Avoid repeated freeze/thaw cycles.
 

Kits storage instructions

Store at 2-8°C. Please refer to Instruction Manual.
 
  1. Myosin light chain 9 promotes the proliferation, invasion, migration and angiogenesis of colorectal cancer cells by binding to Yes-associated protein 1 and regulating Hippo signaling IF: 3.269
    Colorectal cancer is a common type of cancer with high incidence and poor prognosis. Increased expression of myosin light chain 9 (MYL9) has been reported in early-stage and recurrent colorectal cancer tissues.
  2. Expression of lysyl oxidase-like 2 in cholangiocarcinoma and its relations with vascular endothelial growth factor A and angiogenesis IF: 1.772
    To investigate the expression of lysyl oxidase-like 2 (LOXL2) in cholangiocarcinoma (CCA) and its association with angiogenesis in CCA.The relevant data were downloaded from the GEO database, and then, the difference in LOXL2 mRNA expression between CCA tissue and tumor adjacent tissue was compared.
  3. The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma IF: 3.571
    Cholangiocarcinoma (CCA) is the second most common hepatobiliary cancer after hepatocellular carcinoma. Antiangiogenic therapy has been administered to patients with CCA, but the benefits of this therapy remain unsatisfactory. Improved understanding of the molecular mechanisms underlying angiogenesis in CCA is required.
  4. Macc1 promotes angiogenesis in cholangiocarcinoma by upregulating VegFa IF: 3.046
    Angiogenesis actively contributes to tumor growth and metastasis. MACC1 was reported to be associated with tumor progression. In the present study, we aimed to investigate the expression and role of MACC1 in cholangiocarcinoma (CCA) and its correlation with angiogenesis.